Biotech Commercialization: Strategic Insights for Asset Development, Deal-Making and Market Access

As the biotech industry continues to rapidly evolve, staying ahead of the curve requires agile decision-making and robust commercialization strategies.

In this webinar, the expert speakers will explore the key trends and challenges shaping today’s biotech landscape and provide actionable insights for navigating deals, evaluating assets and preparing for successful product launches.

In a time of shifting macroeconomic conditions, with fluctuating capital markets and rising interest rates, deal structures in biotech are undergoing significant changes. The expert speakers will thus examine how these factors influence deal-making strategies, highlighting emerging global hotspots in areas such as oncology and rare diseases.

They will also explore how market trends and evolving patient needs are driving asset valuation and risk mitigation strategies. From early-stage development to late-stage pipeline decisions, they will highlight critical go/no-go decisions, assessing whether an independent path or partnership offers the most value and the potential for long-term success.

In this webinar, attendees will gain insights into the latest market access trends, such as the increasing emphasis on personalized medicine and patient-centric solutions. The expert speakers will offer practical guidance on building the necessary infrastructure for market entry, including regulatory filings, reimbursement strategies and supply chain coordination.

This webinar is designed for biotech executives and investors seeking to navigate strategic partnerships and acquisitions, create compelling value propositions and ensure launch readiness.

Register for webinar today to gain insights into navigating deal-making, optimizing go/no-go decisions and building commercialization strategies that drive successful product launches in today’s biotech market.

Speakers

Isaac Strauss, Managing Consultant, Life Sciences Strategy, Avalere

Isaac Strauss specializes in helping emerging biotech companies navigate strategic decision-making across product planning, forecasting, competitive intelligence, corporate development and licensing. Isaac has advised clients on market opportunities in areas such as ex-vivo perfusion and cellular immune tolerance, guiding commercialization strategies and operational models in complex therapeutic spaces.

Prior to Avalere, he led commercialization strategy for Janssen/Legend’s cilta-cel, an anti-BCMA CAR-T therapy and supported the launch of this complex autologous cell therapy. His expertise spans oncology, hematology, immunology and rare genetic diseases.

Message Presenter

Mike deMilt, Principal, Market Access, Avalere

Mike deMilt helps life sciences clients navigate market dynamics, optimize pipelines and develop access and commercialization strategies. Before joining Avalere, he served as Vice President at Destum Partners, where he led strategic engagements and advisory mandates, supporting transactions for clients across the US, Europe and global markets.

With over a decade of experience advising companies across all phases of development, Mike has shaped corporate strategy through market and financial analytics. Earlier in his career, he worked at Tetracore, where he contributed to the development of diagnostic technologies for infectious diseases and bioterrorism threats.

Message Presenter

Shirley Bachman, Managing Director, Market Access, Avalere

Shirley Bachman is a Market Access expert advising pharmaceutical and biotech clients on rare disease launches, patient services and commercialization strategies. She has extensive experience in distribution models, hub services, contracting and pricing, including the development of value-based agreements in the orphan and ultra-rare disease space. Before Avalere, Shirley spent over 30 years in biopharma, holding leadership roles at Johnson & Johnson, Medivation and Alnylam.

At Alnylam, she led US Market Access, launching a new RNAi therapeutic modality and securing over 60 value-based agreements with payers. Her expertise spans payer strategy, pricing, account management and channel operations.

Message Presenter

Bryan Jack, Managing Director, Client Partnerships, Avalere

Bryan Jack leads account management and business development for Avalere Health’s life sciences clients. Prior to Avalere, he was a Principal at Mercer, guiding large corporations through the transition to a private health insurance exchange.

He also held consulting roles at Deloitte and Mercer, focusing on Medicaid operations, ACA expansion and waiver programs. Earlier in his career, Bryan worked as a registered healthcare lobbyist and served as a legislative staffer in the US House of Representatives.

Message Presenter